Climb Bio reports Phase 1 CLYM116 data with durable suppression
Climb Bio announced Phase 1 data for CLYM116 showing a ~29-day half-life and rapid, durable APRIL and IgA suppression with favorable tolerability.
Climb Bio announced Phase 1 data for CLYM116 showing a ~29-day half-life and rapid, durable APRIL and IgA suppression with favorable tolerability.Key Highlights:Original SEC Filing: Climb Bio, Inc. [ CLYM ] - 8-K - Sep.
03, 2026This is an AI-powered summary.
It may contain inaccuracies.
Consider ve…